Background: Chinese herbal decoction (CHD) has been extensively used in the treatment of atrophic gastritis (AG) in China and other Far Eastern countries. We conducted a systematic review and meta-analysis to estimate the efficacy and safety of CHD in AG. Materials and Methods: Pubmed, Embase, Cochrane central register of controlled trials (central), VIP, China National Knowledge Infrastructure, Sinomed, Wanfang data were searched (up to December 2015). Randomized controlled trials recruiting patients with AG comparing CHD (alone or with western medicine (WM)) with WM were eligible. Dichotomous data were pooled to obtain relative risk (RR), with a 95% confidence interval (CI). Results: Forty-two articles including 3,874 patients were identified. CHD, used alone or with WM, had beneficial effect over WM in the improvement of clinical manifestations (RR=1.28; 95% CI 1.22-1.34) and pathological change (RR=1.42; 95% CI 1.30-1.54) for AG patients. However, the H. pylori eradication effect of CHD was not supported by the existing clinical evidence, because of the significant study heterogeneity (I 2 >50%) and inconsistency between the primary results and sensitivity analysis. Conclusions: CHD, if prescribed as a complementary therapy to WM, may improve the clinical manifestations and pathological change for AG patients. But its monotherapy for H. pylori eradication is not supported by enough clinical evidence.
Introduction
Atrophic gastritis (AG) is defined as the non-metaplastic and metaplastic atrophy of gastric mucosa which is replaced by connective tissue or glandular structures inappropriate for location, such as intestinal-type epithelium and pyloric-type glands (Rugge et al., 2011) . Epidemiological surveys revealed that the global incidence of AG is about 0-10.9% (Adamu et al., 2010) , and the prevalences are higher in Far Eastern countries (such as China, Japan, and Korea) than those in the western ones (Aoki et al., 2005; Weck and Brenner,2006; Weck et al., 2007) . The persistent H. pylori-related inflammatory condition is one of the most important pathogeneses of AG (Eid and Moss, 2002) , making the risk for intestinal-type gastric cancer 5.13 to 24.71-fold higher in gastritis patients than in normal people (Kato et al., 1992) . H. pylori eradication therapies, such as the one-week combined use of moxifloxacin, tetracycline and lansoprazole, are recommended by the western medicine (WM) system to control AG (Taş et al., 2011 ). However, some recent studies reported that the clinical eradication rate of H. pylori has decreased to an unacceptable low level of 25%-80% (Gisbert et al., 2007; Graham and Fischbach,2010; Gumurdulu et al., 2004) . The main causes of eradication failure are the poor compliance of patients, emerging resistant H. pylori strains and adverse drug reactions (Graham and Fischbach, 2010; Megraud, 2004; Safavi et al., 2015) . The unsatisfactory efficacy and safety in WM emphasize the need for more alternative approaches to the managing AG.
Traditional Chinese Medicine (TCM) has been widely used for treating gastritis in China and other Far Eastern reported); and (5) was the treatment based on TCM symptom types (also called Bianzheng Lunzhi in Chinese (Karchmer,2013) )? (2-properly with detailed description, 1-mentioned but detail not reported, 0-not mentioned or inappropriate). A study with a quality score ≤2 was considered as a study at high risk of bias, a study with a quality score ≥ 5 was considered as a study at low risk of bias, and the left were at moderate risk of bias.
Summary measures and synthesis of results
We undertook separate synthesis for each comparison. Dichotomous data were summarized as relative risk (RR) with 95% Confident Intervals (CIs), and a random effects model (DerSimonian and Laird,1986) was used whether heterogeneity was found in order to gain a more conservative outcome. When the authors reported dichotomous data (effective or ineffective), we retrieved them directly. In studies where multiple strata were given to define improvement, we converted these outcomes into dichotomous data to permit the overall analysis. Since the included study use the same validated criteria for the judgement of cure, we grouped together cure, significant improvement, and improvement as effective and no improvement, deterioration, as ineffective. Publication bias was examined using funnel plot and Egger's tests. Heterogeneity between studies was tested using the inconsistency index (I 
Sensitivity analysis
Because the poor-quality of RCT design might lead to exaggerated estimates of intervention benefit (Kjaergard et al.,2001 ), sensitivity analyses were performed to evaluate the robustness of outcomes and identify sources of heterogeneity. We conducted predesigned sensitivity analyses among studies of low to moderate risk of bias (modified Jadad score ≤2).
Results

Study characteristics and risk of bias
The search strategy was shown in the flow diagram ( Figure 1 2006  1  0  0  0  2  3  Zhao HB  2006  1  0  0  0  0  1  Chen YJ  2007  1  0  0  0  1  2  Luo LB  2007  1  0  0  0  2  3  Zhao M  2007  1  0  0  0  2  3  Ou WE  2008  1  0  0  0  2  3  Wang ZM  2008  1  0  0  0  2  3  Xiao LD  2008  1  0  0  0  0  1  Shi CH  2009  1  0  0  0  2  3  Shu H  2009  1  0  0  0  2  3  Su XH  2009  2  0  0  0  2  4  Li LH  2010  1  0  0  0  0  1  Meng L  2010  1  0  0  0  1  2  Zhang YM  2011  1  0  0  0  2  3  Zhu XP  2013  1  0  0  0  2 1  0  0  0  2  3  Song FL  2009  1  0  0  0  2  3  Liu HR  2010  2  0  0  0  0  2  Kuang YJ  2011  1  0  0  0  2  3  Wang XF  2011  1  0  0  0  2  1  Li SQ  2012  1  0  0  0  2  3  Zhang WH  2012  1  0  0  0  0  1  Han XF  2013  1  0  0  0  2  3  Wang J  2013  1  0  0  0  2  1  Shan Q  2014  1  0  0  0  2  3  Fu HK  2014  1  0  0  0  2  3  Liu DX  2014  1  0  0  0  0 (Figure 2 ). There was statistically significant funnel plot asymmetry (Egger's test p=0.044), suggesting evidence of publication bias or other small study effects.
In subgroup of CHD monotherapy versus WM, six trials reported the eradication rate of H. pylori. There was no significant difference between CHD and WM in H. pylori eradication (RR=1.12, 95% CI 0.95-1.32) (Figure 2) , with significant heterogeneity between studies (I 2 =59%). However, the pooled data suggested that CHD with WM had beneficial effect over WM (RR=1.52, 95% CI 1.14-2.02), with significant heterogeneity between studies (I 2 =76%).
Figure 2:
Efficacy of CHD compared with WM in eradication of H. pylori Note: CHD, Chinese herbal decoction; WM, western medicine; Int. CHD-WM, integrated Chinese herbal decoction and western medicine; 95% CI, 95% confidence interval. Each point on the figure represents a relative risk (RR). The diamond represents the pooled estimate of effect, as calculated according to the random effects model. RR<1 means numerically lower response rate than WM, and RR>1 numerically higher response rate than WM. 95% CI doesn't include the number 1 means statistical difference between the two groups.
Clinical manifestations improvement
In total, 38 trials compared CHD (alone or integrated with WM) with WM involving 3,812 patients reported clinical manifestations improvement rate. There are 173 (8.3%) of 2,091 assigned to CHD (alone or integrated with WM) who failed to improve clinical manifestations, compared with 503 (28.8%) of 1,747 patients allocated to WM (RR=1.28; 95% CI 1.22-1.34), without significant heterogeneity between studies (I 2 =44%) ( Figure 3 ). Evidence of publication bias was observed (Egger's test p=0.000).
In subgroup of CHD monotherapy versus WM, 25 studies reported the clinical manifestations improvement rate. The pooled data suggested that CHD had beneficial effect over WM (RR=1.28, 95% CI 1.22-1.35), without significant heterogeneity between studies (I 2 =34%). While Int. CHD-WM was found to be beneficial over WM alone (RR=1.27, 95% CI 1.16-1.39), with significant heterogeneity between studies (I 2 =60%). There was statistically significant funnel plot asymmetry in the two subgroups (Egger's test p=0.0017, p=0.0019, respectively), suggesting evidence of publication bias. The diamond represents the pooled estimate of effect, as calculated according to the random effects model. RR<1 means numerically lower response rate than WM, and RR>1 numerically higher response rate than WM. 95% CI doesn't include the number 1 means statistical difference between the two groups.
Pathological improvement
Totally, 20 trials compared CHD (alone or integrated with WM) with WM in 1,959 patients reported pathological improvement. 154 (14.9%) of 1034 patients using CHD (alone or integrated with WM) failed to improve pathological change, compared with 360 (46.0%) of 925 patients using WM (RR=1.42; 95% CI 1.30-1.54), without significant heterogeneity between studies (I 2 =48%) ( Figure 4 ). Evidence of publication bias was observed (Egger's test p=0.002). In subgroup of CHD monotherapy versus WM, 13 studies reported pathological improvement rate. The result suggested that CHD had beneficial effect over WM (RR=1.33, 95% CI 1.22-1.45), without significant heterogeneity between studies (I 2 =36%). 
Figure 4: Efficacy of CHD compared with WM in pathological improvement
Note: CHD, Chinese herbal decoction; WM, western medicine; Int. CHD-WM, integrated Chinese herbal decoction and western medicine; 95% CI, 95% confidence interval. Each point on the figure represents a relative risk (RR). The diamond represents the pooled estimate of effect, as calculated according to the random effects model. RR<1 means numerically lower response rate than WM, and RR>1 numerically higher response rate than WM. 95% CI doesn't include the number 1 means statistical difference between the two groupAdverse events Only minor side effects, such as urticarial, rash, and slight gastrointestinal discomfort, were found in CHD group (shown in Supplementary Table 2 ). There are no statistical differences in side effects between CHD (alone or with WM) and WM.
Sensitivity analysis
In order to evaluate the robustness of outcomes and identify sources of heterogeneity, we conducted prespecified sensitivity analyses. Totally 25 RCTs are at moderate risk of bias, 18 are at high risk of bias. In subgroup of CHD monotherapy the number is 15 (moderate) and six (high), while in subgroup of Int. CHD-WM the number is 10 (moderate) and 11 (high) (see Supplementary Table 1) . The results were similar in direction and magnitude to the primary results expect the eradication rate of H. pylori, suggesting the robustness of most results in this study. However heterogeneity between trials still existed in the some outcomes (Table 1) . 
Discussion
Herbal decoction is a concentrated herbal tea in which raw roots, berries and barks are lightly simmered for hours to extract the useful constituents. Compared with Chinese herbal patent medicines, which is the ready-made pills or capsules of herbal extracts as products of modern pharmaceutical industry, CHD is considered to have more advantages such as flexibility in treatment and strictly following the basic TCM theory of Bianzheng Lunzhi strictly. Our study is the first systematic review and meta-analysis evaluating the efficacy and safety of all kinds of decoctions in the treatment of AG according to TCM symptom types. The results demonstrated that: 1) CHD may be more effective than WM in ameliorating clinical manifestations of AG; 2) CHD may be more effective than WM in reverting the precancerous lesions of AG; 3) CHD with WM may be more effective than WM in reverting the precancerous lesion of AG. Evidence from sensitivity analyses revealed that the primary results were relatively stable. However, similar conclusions cannot be drawn in the H. pylori eradication rate because of the significant heterogeneity between studies (I 2 ＞50%) and low robustness confirmed by sensitivity analysis. The source of the significant heterogeneity was failed to be identified by sensitivity analysis and subgroup analysis.
Our findings supported the clinical use of CHD for the alleviation of AG-related symptoms and pathologic change, which is consistent with the evidence from previous experimental studies. Pathologic . However, the clinical efficacy of CHD to eradicate H. pylori in AG patients could not be concluded in the present study. We hypothesized the clinical and pathologic improvement of AG patients were more likely to be caused by the strong activity of CHD to inhibit H. pylori-related inflammation, than the eradication of H. pylori itself. Hence, we recommended that CHD be used as an adjunctive therapy to WM, but not used as an alternative to antibiotics for H. pylori eradication.
We included various decoctions for treating different TCM symptom types related to AG, and used the modified Jadad scale with a new scoring item of Bianzheng Lunzhi. This study design made our research strictly follow the TCM therapeutic theory. The basic therapeutic theory of Bianzheng Lunzhi is fundamentally different from that of WM. In the Bianzheng Lunzhi theory, a TCM physician should take the body, mind and spirit into account to decide which symptom type (not a "disease") each patient belongs to (Chen et al., 2003) . Based on TCM syndrome differentiation, diseases should be further classified into different clinical types for therapy. Hence, different kinds of decoctions can be used, and dosage and/or formula in a certain decoction can be added or subtracted according to individual's symptom types and changing states of disease. The personalized therapy according to the symptom type differentiation is the guarantee of its efficacy and should be integrated into clinical trial design (Flower et al., 2012) . Unlike previous studies focusing on a certain herb or decoction, our study adequately considered this individual-based therapeutic features, and made an overall evaluation of all kinds of prescriptions such as Chai-Hu-Shu-Gan decoction, Shan-Jia-Yu -Wei decoction, Jian-Pi-Yi-Wei decoction, and Gan-Cao-Xie-Xin decoction for various TCM symptom types.
Limitations of this review are as follows. Firstly, all the 42 articles that met the eligible criteria were at moderate to high risk of bias. Although sensitivity analyses excluding studies at high risk of bias found that the results were relatively stable, potential bias would exaggerate the efficacy to some extent (Kjaergard et al., 2001 ). Secondly, heterogeneity was observed in some results, especially the results of eradication rate of H. pylori. However, source of heterogeneity was failed to be identified by sensitivity analysis and subgroup analysis. Thirdly, publication bias, which might come from language bias, would potentially compromise the validity of some results and led to optimistic outcomes for treatment. Fourthly, our findings provided insufficient precision in the correlation between medical herbs and clinical outcomes. In fact, practitioners of Chinese medicine always prescribe mixtures of plants (decoction) instead of single plant as therapy. Therefore most RCTs regarding traditional Chinese medicine for atrophic gastritis is designed to evaluate the efficacy of decoctions. It is hard for us to evaluate the efficacy of certain plant for gastritis management using the meta-analysis. Last but not least, the herbs mentioned in all the included studies were not validated taxonomically. Although an overall analysis on efficacy of CHD for AG could be performed based on these studies, the inadequate taxonomical information limited the further species-level review on some specific herbs.
Conclusions
We recommended that CHD be prescribed as a complementary therapy to WM for atrophic gastritis, but its monotherapy for H. pylori eradication is not confirmed by existing clinical evidence. The evidence should be further strengthened because studies at low risk of bias were scarce. More large-scale, multicenter, prospective RCTs are needed therefore. We believe this article will stimulate further evaluation of CHD for AG therapy.
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